EGLN3 and pancreatic neoplasm: Several studies show that PHD3 is overexpressed in pancreatic cancer and might influence patient survival [84], although, these observations appear paradoxical in the sense that increased levels of PHD activity have tumor suppressor function, it remains clear that elevated PHD3 is associated with aggressive pancreatic cancer and poor patient outcome [85].